Organon Presents New Analysis of VTAMA Cream Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

Organon's VTAMA cream, indicated for atopic dermatitis (AD) in adults and pediatric patients 2 years and older, has demonstrated early and consistent skin clearance and itch improvement in a post-hoc sub-analysis of pooled data from Phase 3 trials. Significant improvements in vIGA-AD, EASI75, and PP-NRS response rates were observed as early as week 1 and continued through week 8. The findings suggest VTAMA cream's potential in addressing common AD symptoms and provide evidence for its use in managing the disease.